2010/07/12 > eTech France 244 > Bioanalyses - Promising Collaboration between Indicia Biotechnology and Singulex Inc.

Coordonnées >> Toute l'actualité : France >> Monde >> Tous les rapports : France >> Monde >> Tous les flux rss >>		eTech France 244 >> 12/07/2010	>> Sommaire

		Special Feature Bioanalyses - Promising Collaboration between Indicia Biotechnology and Singulex Inc. http://www.bulletins-electroniques.com/actualites/64024.htm Indicia Biotechnology is a business with some fifty employees located in Oulins near Lyons. Based on its skills and expertise in immunotechnology and biochemistry, it provides support to biotechnology companies and pharmaceutical industry operators for the design, development and manufacture of in vitro diagnostic reagents and bioanalysis methods. At the BIO International Convention in Chicago this May, Indicia Biotechnology announced an industrial collaboration with California based Singulex Inc., created some ten years ago. CEO Stéphane Legastelois of the Rhone-Alps business explains the importance of the collaboration for both partners, which is expected to broaden over the coming years. Interview by Jean-François Desessard. BE France - How did the collaboration with Singulex Inc. get started? Stéphane Legastelois - Indicia Biotechnology offers its customers the development of immunoanalysis methods based on technological platforms. In the field of bioanalysis services for business, either pharmaceutical or life science companies, technologies are ever-changing. So, it is critical for us to be able to offer increasingly sensitive systems for dosing biomarkers at increasingly lower sensitivity levels. Singulex Inc. has engineered a technology for biomarker quantification at the femtogram level, in other words at a sensitivy level never before reached in immunoanalysis. Today the original technology is mature and, after initial sales in the United States, the California based company is looking to develop sales in Europe via a partner able to supply services to European companies. So, the management of the US company came to Lyons where we met and were able to see the relative consistency between our respective approaches. BE France - You have just acquired the technology engineered by Singulex Inc. What are the next stages? Stéphane Legastelois - We will be using the technology to quantify biomarkers in biological samples, for instance for clinical trials conducted by pharmaceutical companies. Therefore, we will be offering our customers an immunoanalysis 'testing' service. It will also be our added value as we will be able to develop new tests based on the technology that now offers a menu of some fifty dosable molecules. Indicia Biotechnology provides 'custom-made' molecules as every customer needs a special molecule particular to their needs, which is not part of the preexisting menu. We will begin by developing the method for a given molecule and then validate it. Singulex Inc. has granted us a world exclusive for the developments. BE France - In addition to your collaboration, Singulex Inc. has decided to set up its European subsidiary in Lyons. Will this prompt you to broaden your collaboration? Stéphane Legastelois - Above all, Singulex Inc. was looking for a platform that could disseminate their technology, i.e., the one available at Indicia Biotechnology. They needed to set up a light facility that could provide customer support, a task that could not be directly managed from the United States. However, Singulex Inc. management would also like to put together other possible collaborative projects to develop new methods applicable to other pathologies. So, we will soon be starting our first joint work on an inflammatory disease. The collaboration between Indicia Biotechnology and Singulex Inc. that has just started should broaden in the coming years.	>> Suivant << Précédent Version imprimable >> Transmettre cette info par email >> Recommander ce site à un collègue / ami >> S'abonner au eTech France >> FAQ / foire aux questions >> Conditions d'utilisation >>


	Pour en savoir plus, contacts :	Indicia Biotechnology - Stéphane Legastelois, CEO - Phone: +33 (0)4 72 39 14 92 - email: slegastelois@indicia.fr - http://www.indicia.fr	Code brève ADIT : 64024

	Rédacteur :	ADIT - Jean-François Desessard - email: jfd@adit.fr


	Origine :	eTech France numéro 244 (12/07/2010) - ADIT / ADIT - http://www.bulletins-electroniques.com/actualites/64024.htm

[ Plan du site | Données personnelles & politique de confidentialité | Limites de responsabilité | FAQ | Contacts ]

4444444006 999920100713 3333333061 1010101016 1010101013 1111111049 55555550072010 6666666063 7777777001